These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Preference procedures for testing the abuse liability of drugs in humans. De Wit H Br J Addict; 1991 Dec; 86(12):1579-86. PubMed ID: 1786490 [TBL] [Abstract][Full Text] [Related]
9. Protection of participants and experimental design in clinical abuse liability testing. Mendelson JH Br J Addict; 1991 Dec; 86(12):1543-8. PubMed ID: 1786485 [TBL] [Abstract][Full Text] [Related]
10. Regulation and abuse liability testing of medicines in Europe beyond 1992. García Alonso F Br J Addict; 1991 Dec; 86(12):1533-6. PubMed ID: 1786483 [TBL] [Abstract][Full Text] [Related]
11. The role of human drug self-administration procedures in the development of medications. Comer SD; Ashworth JB; Foltin RW; Johanson CE; Zacny JP; Walsh SL Drug Alcohol Depend; 2008 Jul; 96(1-2):1-15. PubMed ID: 18436394 [TBL] [Abstract][Full Text] [Related]
12. The necessity and utility of abuse liability evaluations in human subjects. Vocci FJ Br J Addict; 1991 Dec; 86(12):1537-42. PubMed ID: 1786484 [TBL] [Abstract][Full Text] [Related]
13. Drug metabolism and interactions in abuse liability assessment. Sellers EM; Otton SV; Busto UE Br J Addict; 1991 Dec; 86(12):1607-14. PubMed ID: 1786494 [TBL] [Abstract][Full Text] [Related]
14. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse. Swedberg MD J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786 [TBL] [Abstract][Full Text] [Related]
15. The evaluation of the abuse liability of drugs. Johanson CE Drug Saf; 1990; 5 Suppl 1():46-57. PubMed ID: 2182063 [TBL] [Abstract][Full Text] [Related]
16. Guidelines and methodological reviews concerning drug abuse liability assessment. Balster RL; Bigelow GE Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195 [TBL] [Abstract][Full Text] [Related]
17. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models. Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211 [TBL] [Abstract][Full Text] [Related]
18. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. Busto UE; Zawertailo LA; Kaplan HL; Sellers EM Can J Clin Pharmacol; 1999; 6(2):103-10. PubMed ID: 10519736 [TBL] [Abstract][Full Text] [Related]
19. Current approaches and issues in non-clinical evaluation of abuse and dependence. Moser P; Wolinsky T; Castagné V; Duxon M J Pharmacol Toxicol Methods; 2011; 63(2):160-7. PubMed ID: 20868759 [TBL] [Abstract][Full Text] [Related]
20. Human abuse liability evaluation of CNS stimulant drugs. Romach MK; Schoedel KA; Sellers EM Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]